Symfaxin ER, 37.5 mg, prolonged-release hard capsules
Venlafaxine
Symfaxin ER contains the active substance venlafaxine.
Symfaxin ER is an antidepressant that belongs to a group of medicines called serotonin and noradrenaline reuptake inhibitors (SNRIs). These medicines are used to treat depression and other conditions, such as anxiety disorders. It is thought that in people with depression and/or anxiety, there is a lower level of serotonin and noradrenaline in the brain.
The mechanism of action of antidepressants is not fully understood, but they may help by increasing the levels of serotonin and noradrenaline in the brain.
Symfaxin ER is used to treat depression in adults. Symfaxin ER is also used to treat the following anxiety disorders in adults: generalized anxiety disorder, social anxiety disorder (fear or avoidance of social situations), and panic disorder (panic attacks). For the patient to feel better, it is essential that the treatment of depression and anxiety disorders is carried out correctly. If the patient does not undergo treatment, their condition may not improve, may worsen, and will be much more difficult to treat.
"Symfaxin ER with other medicines" and the information in that section about serotonin syndrome.
Before starting treatment with Symfaxin ER, you should discuss it with your doctor or pharmacist:
Symfaxin ER may cause a feeling of restlessness or an inability to sit or stand still during the first few weeks of treatment. If such symptoms occur, you should inform your doctor.
Do not drink alcohol during treatment with Symfaxin ER, as it may cause extreme fatigue and loss of consciousness. Taking Symfaxin ER with alcohol and/or certain other medicines may increase the risk of side effects, such as worsening of depression and other conditions, such as anxiety disorders.
Suicidal thoughts and worsening of depression or anxiety disorders
People with depression and/or anxiety disorders may sometimes have thoughts of self-harm or suicide. Such symptoms or behavior may worsen at the start of treatment with antidepressants, as these medicines start to work usually after 2 weeks, and sometimes later.
The risk of suicidal thoughts or self-harm is higher if:
If you experience suicidal thoughts or self-harm, you should contact your doctor or go to the hospital immediately.
It may be helpful to inform your relatives or friends about your depression or anxiety disorder and ask them to read this leaflet. You may want to ask your relatives or friends to tell you if they notice that your depression or anxiety has worsened and if you have any disturbing changes in your behavior.
Dry mouth
Dry mouth was reported by 10% of patients treated with venlafaxine. It may increase the risk of tooth decay. Therefore, you should pay special attention to oral hygiene.
Diabetes
Symfaxin ER may affect blood sugar levels, and it may be necessary to adjust the dose of your antidiabetic medicines.
Medicines like Symfaxin ER (so-called SSRIs or SNRIs) may cause sexual dysfunction (see section 4). In some cases, these symptoms have persisted after stopping treatment.
Symfaxin ER should not be used in children and adolescents under 18 years of age. It should also be noted that patients under 18 years of age who take medicines of this class are at increased risk of side effects, such as suicide attempts, suicidal thoughts, and hostility (especially aggression, rebelliousness, and anger). However, your doctor may prescribe Symfaxin ER to patients under 18 years of age if they consider it to be beneficial. If your doctor has prescribed Symfaxin ER to a patient under 18 years of age, and you have any concerns, you should discuss them with your doctor. You should inform your doctor if any of these symptoms occur or worsen in patients under 18 years of age taking Symfaxin ER. The long-term safety of Symfaxin ER on growth, maturation, and cognitive and behavioral development in this age group has not been established.
Tell your doctor or pharmacist about all the medicines you are taking now or have taken recently, and about any medicines you plan to take.
Your doctor will decide whether you can take Symfaxin ER with other medicines.
Do not start or stop taking other medicines, including those available without a prescription, herbal products, or dietary supplements, without consulting your doctor or pharmacist first.
The subjective and objective symptoms of serotonin syndrome may include: restlessness, hallucinations, loss of coordination, rapid heart rate, elevated body temperature, rapid changes in blood pressure, overreactivity, diarrhea, coma, nausea, vomiting.
The most severe form of serotonin syndrome may resemble neuroleptic malignant syndrome (NMS). The symptoms of NMS may include fever, rapid heart rate, sweating, muscle stiffness, disorientation, elevated levels of muscle enzymes (detected in blood tests),
If you are taking medicines that may affect your heart rhythm, you should tell your doctor. Examples of such medicines include:
The following medicines may also interact with Symfaxin ER, and you should use them with caution. It is especially important to inform your doctor or pharmacist if you are taking medicines containing:
Symfaxin ER should be taken with food (see section 3 "How to take Symfaxin ER").
Do not drink alcohol during treatment with Symfaxin ER. Taking Symfaxin ER with alcohol may cause extreme fatigue and loss of consciousness, as well as worsening of depression and other conditions, such as anxiety disorders.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Symfaxin ER should only be used after discussing the potential benefits and risks to the unborn child with your doctor.
You should inform your doctor and/or midwife if you are taking Symfaxin ER. Similar medicines (SSRIs) taken during pregnancy may increase the risk of a serious condition in children and/or infants, called persistent pulmonary hypertension of the newborn (PPHN), which causes rapid breathing and bluish discoloration. These symptoms usually occur within 24 hours of birth. If you notice such symptoms in your child, you should contact the midwife and/or doctor immediately.
If you have taken this medicine during pregnancy, your newborn baby may experience withdrawal symptoms, such as difficulty feeding, which you should discuss with your doctor and/or midwife.
Taking Symfaxin ER at the end of pregnancy may increase the risk of severe bleeding from the vagina, which occurs shortly after delivery, especially if you have a history of bleeding disorders. If you are taking Symfaxin ER, you should inform your doctor or midwife so that they can provide you with appropriate advice.
Symfaxin ER passes into breast milk. There is a risk to the baby. You should discuss this with your doctor, who will decide whether you should stop breastfeeding or stop Symfaxin ER treatment.
Do not drive or operate machinery until you know how Symfaxin ER affects you.
Symfaxin ER, 150 mg contains orange yellow S (E110), which may cause allergic reactions.
This medicine should always be taken exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
The usual recommended starting dose for depression, generalized anxiety disorder, and social anxiety disorder is 75 mg once daily. Your doctor may gradually increase the dose if necessary, up to a maximum dose of 375 mg once daily for depression. For panic disorder, treatment should be started with a lower dose (37.5 mg) and then gradually increased. The maximum dose for generalized anxiety disorder, social anxiety disorder, and panic disorder is 225 mg once daily.
Symfaxin ER should be taken once daily, at approximately the same time, regardless of whether it is morning or evening. The capsules should be swallowed whole with a drink of water. Do not open them, crush them, chew them, or dissolve them.
Symfaxin ER should be taken with food.
You should inform your doctor about any liver or kidney problems, as it may be necessary to adjust the dose.
Do not stop taking this medicine without consulting your doctor (see section "Stopping Symfaxin ER treatment").
If you have taken more Symfaxin ER than prescribed, you should contact your doctor or pharmacist immediately.
Overdose can be life-threatening, especially when taken with alcohol and/or certain other medicines (see section "Symfaxin ER with other medicines").
Symptoms of possible overdose may include rapid heart rate, changes in consciousness (from drowsiness to coma), visual disturbances, seizures, and vomiting.
If you miss a dose, you should take it as soon as possible. However, if it is almost time for your next dose, you should skip the missed dose and take only one dose at the usual time. Do not take a double dose to make up for a missed dose. Do not take more than the prescribed daily dose of Symfaxin ER.
Do not stop taking this medicine without consulting your doctor, even if you feel better. If your doctor decides that you can stop taking Symfaxin ER, they will tell you how to gradually reduce the dose before stopping treatment completely. When stopping treatment, especially after sudden discontinuation or too rapid dose reduction, you may experience side effects, such as fatigue, dizziness, headache, insomnia, nightmares, dry mouth, loss of appetite, nausea, diarrhea, nervousness, agitation, disorientation, ringing in the ears, tingling, or electric shock-like sensations, weakness, sweating, seizures, or flu-like symptoms.
Your doctor will advise you on how to gradually stop taking Symfaxin ER. If you experience any of these symptoms or other symptoms that are bothersome to you, you should consult your doctor.
If you have any further questions about taking this medicine, you should ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you experience any of the following side effects, you should stop taking Symfaxin ER and contact your doctor or go to the hospital immediately:
If you experience any of the following side effects, you should contact your doctor:
has been absorbed.
Symfaxin ER may also cause side effects that you may not be aware of, such as increased blood pressure or abnormal heart rhythm; slight changes in liver enzyme activity, sodium levels, or cholesterol levels in the blood.
In rare cases, Symfaxin ER may affect platelet function, increasing the risk of bruising or bleeding. Therefore, your doctor may recommend regular blood tests, especially during long-term treatment with Symfaxin ER.
If you experience any side effects, including any not listed in this leaflet, you should tell your doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety, Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych, Al. Jerozolimskie 181C, 02-222 Warszawa, tel.: + 48 22 49 21 301, fax + 48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the carton and blister after EXP.
The expiry date refers to the last day of that month.
Store in the original package to protect from moisture.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Symfaxin ER, 37.5 mg, prolonged-release hard capsules
Core of the capsule:
Microcrystalline cellulose
Povidone K 90
Talc
Colloidal anhydrous silica
Magnesium stearate
Coating:
Ethylcellulose
Copovidone
Body of the capsule:
Black iron oxide (E 172)
Red iron oxide (E 172)
Titanium dioxide (E 171)
Gelatin
Red ink for printing
Cap of the capsule:
Black iron oxide (E 172)
Red iron oxide (E 172)
Yellow iron oxide (E 172)
Titanium dioxide (E 171)
Gelatin
Red ink for printing
Symfaxin ER, 75 mg, prolonged-release hard capsules
Core of the capsule:
Microcrystalline cellulose
Povidone K 90
Talc
Colloidal anhydrous silica
Magnesium stearate
Coating:
Ethylcellulose
Copovidone
Body and cap of the capsule:
Black iron oxide (E 172)
Red iron oxide (E 172)
Titanium dioxide (E 171)
Gelatin
Red ink for printing
Symfaxin ER, 150 mg, prolonged-release hard capsules
Core of the capsule:
Microcrystalline cellulose
Povidone K 90
Talc
Colloidal anhydrous silica
Magnesium stearate
Coating:
Ethylcellulose
Copovidone
Body and cap of the capsule:
Brilliant blue FCF (E 133)
Allura red AC (E 129)
Orange yellow S (E 110)
Titanium dioxide (E 171)
Gelatin
White ink for printing
Symfaxin ER, 37.5 mg, prolonged-release hard capsules
Hard, non-transparent, grey-orange gelatin capsules with a thick and thin red ring on the body and a thick and thin red ring on the cap. The capsule contains 3 white or off-white, round, biconvex, film-coated pellets.
Symfaxin ER, 75 mg, prolonged-release hard capsules
Hard, non-transparent, orange-orange gelatin capsules with a thick and thin red ring on the body and a thick and thin red ring on the cap. The capsule contains 6 white or off-white, round, biconvex, film-coated pellets.
Symfaxin ER, 150 mg, prolonged-release hard capsules
Hard, non-transparent, dark orange-dark orange gelatin capsules with a thick and thin white ring on the body and a thick and thin white ring on the cap. The capsule contains 12 white or off-white, round, biconvex, film-coated pellets.
Symfaxin ER, 37.5 mg: 10, 28, and 30 capsules.
Symfaxin ER, 75 mg and 150 mg: 14, 28, and 30 capsules.
The capsules are packaged in blisters. The blisters are packaged in cardboard boxes.
Not all pack sizes may be marketed.
Farmak International Sp. z o.o.
ul. Koszykowa 65
00-667 Warszawa
Farmak International Sp. z o.o.
ul. Chełmżyńska 249
04-458 Warszawa
PL: Symfaxin ER
Date of last revision of the leaflet:May 2025
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.